Eculizumab
CAS 219685-50-4 1 FDA-DMF supplierBiologic
Overview
Eculizumab is a monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome by inhibiting the complement component C5. It prevents the destruction of blood cells and can improve kidney function and reduce symptoms of these diseases.
Therapeutic areas
HematologyNephrologyNeurology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.